Skip to content Skip to footer
Subscribe Now
Viewpoints_Paula Ragan
VIEWPOINTS
Pharmashots Interview: Paula Ragan Shares Insights on the Data of Mavorixafor in Combination with Ibrutinib Presented at 2021 EHA Annual Congress
In an interview with PharmaShots, Paula Ragan, Ph.D., President, and Chief Executive Officer at X4 Pharmaceuticals shared her views on preliminary efficacy and safety data of Mavorixafor + Ibrutinib in an ongoing P-Ib study to treat waldenström's macroglobulinemia Shots: The ongoing P-Ib clinical trial evaluates the safety & efficacy of mavorixafor + ibrutinib in patients with WM with both MYD88 &…
September 3, 20210Comments
Viewpoints_Michael Dale
VIEWPOINTS
PharmaShots Interview: Abbott’s Michael Dale Shares Insight on the CE Mark for the Next-Generation Navitor TAVI System
In an interview with PharmaShots, Michael Dale, Senior Vice President of the Structural Heart division at Abbott shared his views on the Navitor's approval in the EU for patients with severe aortic stenosis who are at high or extreme surgical risk for open-heart surgery. Shots: Abbott has received CE Mark approval for its latest-generation transcatheter aortic…
September 3, 20210Comments
Insights+ Key Biosimilars Events of August 2021
INSIGHTS+
Insights+ Key Biosimilars Events of August 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of August, Samsung Bioepis Byooviz (biosimilar, ranibizumab) received EC's…
September 2, 20210Comments
Viewpoints_Rami Levin
VIEWPOINTS
PharmaShots Interview: Saniona’s Rami Levin Shares Insight on Tesomet for Hypothalamic Obesity
In an interview with PharmaShots, Rami Levin, Chief Executive Officer at Saniona shared his views on the US FDA's Orphan Drug Designation (ODD) to Tesomet for the treatment of hypothalamic obesity (HO) and discuss its role in the company's continued pipeline progress. Shots: Saniona reported that the FDA has granted orphan drug designation to Tesomet for the…
August 27, 20210Comments
Thoughtspot_Senior Editor
THOUGHTSPOT
Over Prescribed Medications and its Impact
Introduction: 'Over-prescription' is defined as the action of prescribing a drug or treatment in greater amount or on more occasions than necessary. Overprescribing, in general in health care, has been a subject of frequent study. For instance, research published in 2018 found that 46% of a half-million outpatient antibiotic prescriptions were written by clinicians without diagnoses of…
August 26, 20210Comments
Viewpoints_Avanish Vellanki
VIEWPOINTS
PharmaShots Interview: Rain Therapeutic’s Avanish Vellanki Shares Insight on the Initiation of P-III MANTRA Trial of Milademetan for Dedifferentiated Liposarcoma
In an interview with PharmaShots, Avanish Vellanki, CEO and Cofounder at Rain Therapeutics shared his views on the initiation of the P-III MANTRA trial to evaluate the safety & efficacy of Milademetan for dedifferentiated liposarcoma and provide updates about the company's lead candidate, RAIN-32. Shots: The company initiates P-III MANTRA trial to evaluate safety & efficacy of…
August 23, 20210Comments
Viewpoints_Jonathan Rigby
VIEWPOINTS
PharmaShots Interview: Revolo’s Jonathan Rigby Shares Insights on the ‘1104 for Eosinophilic Esophagitis
In an interview with PharmaShots, Jonathan Rigby, Group Chief Executive Officer at Revolo Biotherapeutics shared his views on the unique mechanism of '1104 and discuss the plan of the company's clinical studies. Shots: Revolo reported the US FDA's approval to initiate a P-II clinical trial evaluating the safety and efficacy of '1104 in adults with EoE '1104 is a…
August 18, 20210Comments
Viewpoints_Jonathan Rigby
VIEWPOINTS
PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insight About the New AGA Guidelines Recommending Stelara (Ustekinumab) as a First-Line Treatment Option in Crohn’s Disease
In an interview with PharmaShots, Andrew Greenspan, VP, Immunology Affairs at Janssen shared his views on the new AGA guidelines on the medical management of moderate-to-severe Crohn's disease and also highlighted about Janssen's efforts in improving the QoL of patients with CD The AGA guidelines assessed the overall benefit of each drug and also compared…
August 17, 20210Comments

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]